SCHEMBL5654708

SCHEMBL5654708

COC(=O)CCCCCNC(=O)[C@H](CCCNC(=O)OCc1ccccc1)NCc1ccc(-c2ccccc2)cc1

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MMP2 P08253 3/20 0.53
MMP9 P14780 3/20 0.53
TLR2 O60603 1/20 0.52
PTGER4 P35408 3/20 0.51
FOLH1 Q04609 2/20 0.51
CPB1 P15086 1/20 0.50
CPB2 Q96IY4 1/20 0.50
MMP1 P03956 1/20 0.49
MMP3 P08254 1/20 0.49
MMP7 P09237 1/20 0.49
MMP13 P45452 1/20 0.49
SIRT2 Q8IXJ6 6/20 0.49
SIRT1 Q96EB6 4/20 0.49
SIRT3 Q9NTG7 3/20 0.49
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
HPGD P15428 1/20 0.48
KMT2A Q03164 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5656638 0.90 MMP2 (0.56) MMP2MMP9TLR2PTGER4FOLH1
SCHEMBL5656118 0.86 PTGER4 (0.59) MMP2MMP9PTGER4FOLH1CPB1
SCHEMBL5656235 0.84 MMP2 (0.47) MMP2MMP9FOLH1CPB1CPB2
SCHEMBL5653166 0.83 PTGER4 (0.62) PTGER4FOLH1CPB1CPB2SIRT2
SCHEMBL5654338 0.82 PTGER4 (0.56) PTGER4FOLH1CPB1CPB2SIRT2
SCHEMBL3065465 0.82 HTT (0.68) FOLH1SIRT2SIRT1SIRT3
SCHEMBL131437 0.82 HTT (0.68) FOLH1SIRT2SIRT1SIRT3
SCHEMBL5651760 0.81 MAPT (0.57) PTGER4SIRT2SIRT1SIRT3MEN1
Hydrochloric Acid SCHEMBL5654724 0.81 ANPEP (0.57) PTGER4FOLH1SIRT2SIRT1SIRT3
SCHEMBL23223918 0.81 HTT (0.69) FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070142638-A1 Ornithine derivatives as prostaglandin e2 agonists or antagonists ASTELLAS PHARMA INC. (JP) 2007-06-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070142638-A1 Ornithine derivatives as prostaglandin e2 agonists or antagonists PTGER4, OXER1, RXFP4 MMP2 3589/4885MMP9 4006/4885TLR2 778/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.